Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
The fund’s strategy, top holdings, and recent portfolio moves are explored to provide insights for existing and potential investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback